Literature DB >> 21856269

Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease.

Manoe J Janssen1, Esmé Waanders, René H M Te Morsche, Ruoyu Xing, Henry B P M Dijkman, Jannes Woudenberg, Joost P H Drenth.   

Abstract

BACKGROUND & AIMS: Heterozygous germline mutations in PRKCSH cause autosomal dominant polycystic liver disease (PCLD), but it is not clear how they lead to cyst formation. We investigated whether mutations in cyst epithelial cells and corresponding loss of the PRKCSH gene product (hepatocystin) contributed to cyst development.
METHODS: Liver cyst material was collected through laparoscopic cyst fenestration from 8 patients with PCLD who had a heterozygous germline mutation in PRKCSH. Tissue sections from 71 cysts (2-14 per patient) were obtained for hepatocystin staining and mutation analysis. Cyst epithelium was acquired using laser microdissection; DNA was isolated and analyzed for loss of heterozygosity (LOH) and somatic mutations using restriction analysis and sequencing. Common single nucleotide polymorphisms (SNPs) in a 70-kilobase region surrounding the germline mutation were used to determine variations in the genomic region with LOH.
RESULTS: The wild-type allele of PRKCSH was lost (LOH) in 76% of cysts (54/71). Hepatocystin was not detected in cyst epithelia with LOH, whereas heterozygous cysts still expressed hepatocystin. The variation observed in the LOH region analysis indicates that cysts develop independently. We also detected somatic mutations in PRKCSH in 17% (2/12) of the cysts without LOH. Trans-heterozygous mutations in SEC63 were not observed.
CONCLUSIONS: Among patients with PCLD who have a heterozygous germline mutation in PRKCSH, we found secondary, somatic mutations (second hits) in more than 76% of the liver cyst epithelia. PCLD is recessive at the cellular level, and loss of functional PRKCSH is an important step in cystogenesis.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21856269     DOI: 10.1053/j.gastro.2011.08.004

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  18 in total

1.  Spliced XBP1 Rescues Renal Interstitial Inflammation Due to Loss of Sec63 in Collecting Ducts.

Authors:  Yasunobu Ishikawa; Sorin Fedeles; Arnaud Marlier; Chao Zhang; Anna-Rachel Gallagher; Ann-Hwee Lee; Stefan Somlo
Journal:  J Am Soc Nephrol       Date:  2019-02-11       Impact factor: 10.121

2.  Sec63 and Xbp1 regulate IRE1α activity and polycystic disease severity.

Authors:  Sorin V Fedeles; Jae-Seon So; Amol Shrikhande; Seung Hun Lee; Anna-Rachel Gallagher; Christina E Barkauskas; Stefan Somlo; Ann-Hwee Lee
Journal:  J Clin Invest       Date:  2015-04-06       Impact factor: 14.808

Review 3.  Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Authors:  Luca Fabris; Romina Fiorotto; Carlo Spirli; Massimiliano Cadamuro; Valeria Mariotti; Maria J Perugorria; Jesus M Banales; Mario Strazzabosco
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

Review 4.  Polycystic liver diseases: advanced insights into the molecular mechanisms.

Authors:  Maria J Perugorria; Tatyana V Masyuk; Jose J Marin; Marco Marzioni; Luis Bujanda; Nicholas F LaRusso; Jesus M Banales
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-09-30       Impact factor: 46.802

Review 5.  Diagnosis and management of polycystic liver disease.

Authors:  Tom J G Gevers; Joost P H Drenth
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-01-08       Impact factor: 46.802

6.  Chromosomal abnormalities in hepatic cysts point to novel polycystic liver disease genes.

Authors:  Edgar S Wills; Wybrich R Cnossen; Joris A Veltman; Rob Woestenenk; Marloes Steehouwer; Jody Salomon; René H M Te Morsche; Meritxell Huch; Jayne Y Hehir-Kwa; Martijn J Banning; Rolph Pfundt; Ronald Roepman; Alexander Hoischen; Joost P H Drenth
Journal:  Eur J Hum Genet       Date:  2016-08-24       Impact factor: 4.246

7.  Somatic second-hit mutations leads to polycystic liver diseases.

Authors:  Jesús M Banales; Patricia Munoz-Garrido; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 8.  Therapeutic Targets in Polycystic Liver Disease.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

9.  Severe Polycystic Liver Disease Is Not Caused by Large Deletions of the PRKCSH Gene.

Authors:  Wybrich R Cnossen; Jake S F Maurits; Jody Salomon; René H M Te Morsche; Esmé Waanders; Joost P H Drenth
Journal:  J Clin Lab Anal       Date:  2015-09-13       Impact factor: 2.352

Review 10.  Polycystin-1: a master regulator of intersecting cystic pathways.

Authors:  Sorin V Fedeles; Anna-Rachel Gallagher; Stefan Somlo
Journal:  Trends Mol Med       Date:  2014-01-31       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.